# OnCo record nct04379635 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04379635/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04379635", "NCT04379635" ;
  schema:name "Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)"@en ;
  schema:alternateName "RATIONALE-315"@en ;
  schema:description "A phase 3 trial of Tislelizumab, Cisplatin, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by BeiGene, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04379635/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04379635>, <https://doi.org/10.1016/j.annonc.2025.11.017> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2020-05-29" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/resectable-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/tislelizumab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/beone/> ;
  onco:trials <https://onco.cc/trials/neotorch/>, <https://onco.cc/trials/nct04025879/>, <https://onco.cc/trials/nct03800134/>, <https://onco.cc/trials/keynote-671/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct04379635-lancet-respir-med-2025/>, <https://onco.cc/key-papers/paper-nct04379635-ann-oncol-2026-update/> .